Simcere Pharmaceutical Group (HKG: 2096) has announced that its oncology subsidiary, Simcere Zaiming Pharmaceutical Co., Ltd., has secured RMB 970 million (USD 135 million) in financing, elevating the company’s market valuation to RMB 8.47 billion (USD 1.2 billion). The funding round was led by CS Capital, which contributed RMB 800 million, while Shenzhen Zhongshenxinchuang Investment and Apricot Capital added RMB 100 million and RMB 50 million, respectively.
Established in December 2020, Simcere Zaiming specializes in drug development for lung cancer, gastrointestinal tumors, and gynecological tumors. The company employs a range of treatment modalities focusing on tumor immunity, cancer-driver genes, and synthetic lethality. Its pipeline includes innovative therapies developed through protein engineering, T cell and NK cell connectors, AI-assisted molecular design, protein degradation agents, and antibody-drug conjugates (ADCs).- Flcube.com
